Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1982;69(1):40-9.
doi: 10.1159/000233144.

Suppression of experimental allergic orchitis and cellular immune response in the guinea pig by pretreatment with testis antigen in incomplete Freund's adjuvant

Suppression of experimental allergic orchitis and cellular immune response in the guinea pig by pretreatment with testis antigen in incomplete Freund's adjuvant

K Hojo et al. Int Arch Allergy Appl Immunol. 1982.

Abstract

Pretreatment of guinea pigs with homologous testicular antigen (TA) in incomplete Freund's adjuvant (IFA) markedly reduced both the incidence and severity of experimental allergic orchitis (EAO) when animals were subsequently challenged with TA in complete Freund's adjuvant (CFA) and examined at 2 weeks after challenge. The pretreatment rendered lymph node lymphocytes, particularly T cells, specifically unresponsive to the subsequent orchitogenic challenge as judged by antigen-induced in vitro lymphocyte proliferative response and blastogenic factor production, whereas antisperm antibody formation was not affected. The suppression induced was of a transitory nature, lasting 3 weeks after orchitogenic challenge, but between 4 and 5 weeks after challenge the development of EAO and aspermatogenesis became evident in parallel with the restoration of cellular immune responsiveness. Cyclophosphamide treatment 3 days before orchitogenic challenge abolished the preventive effect of pretreatment with TA in IFA. Transfer of serum obtained from pretreated animals failed to prevent actively sensitized recipients from developing EAO, which does not favor a possible occurrence of serum blocking factors in protected animals.

PubMed Disclaimer

MeSH terms